Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zhejiang Hisun Pharmaceutical Co. Ltd.

http://www.hisunpharm.com/en/

Latest From Zhejiang Hisun Pharmaceutical Co. Ltd.

Tech Transfer Roundup: Hoth Teams With VCU On Therapy To Block COVID-19 Replication

Pandemic-related collaborations between Hoth/VCU; Sorrento/Mt. Sinai Health; Audax/Northeastern U.; Alkido/U. of Maryland, Baltimore; Active Motif/Hisun BioRay/Fudan U. and more.

Deals Coronavirus COVID-19

India Panel Favors Favipiravir, Tocilizumab As It Assesses COVID-19 Treatments

In a preliminary assessment of repurposed COVID-19 treatments by a government-appointed panel to assess the readiness and potential of a drug to be used in India, favipiravir and tocilizumab have emerged as front-runners. With Strides Pharma exporting the antiviral and Glenmark set to begin clinical trials, even the industry is supporting favipiravir, which is already in studies in Japan and China.

Coronavirus COVID-19 Commercial

As China Rushes Medical Supplies To World, Quality Issues Resurface

As China is poised to supply medical products to fight the coronavirus around the world, a battle to banish its image of poor product quality is on.

Quality Regulation

India COVID-19 Update: Antivirals, Eyes On HCQ-Azithromycin Data

Development work for antivirals such as favipiravir and remdesivir seen as potential treatments for coronavirus is underway in India, with the former’s off-patent status making it more attractive. All eyes are also on data from a French study which highlights the potential of hydroxychloroquine and azithromycin as a COVID-19 treatment.

Research & Development Coronavirus COVID-19
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Hisun-Pfizer Pharmaceuticals Co., Ltd.
UsernamePublicRestriction

Register